Related references
Note: Only part of the references are listed.Meta-analysis: Effect of Patient Self-testing and Self-management of Long-Term Anticoagulation on Major Clinical Outcomes
Hanna E. Bloomfield et al.
ANNALS OF INTERNAL MEDICINE (2011)
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial
John W. Eikelboom et al.
CIRCULATION (2011)
Dabigatran Versus Warfarin in Patients With Atrial Fibrillation An Analysis of Patients Undergoing Cardioversion
Rangadham Nagarakanti et al.
CIRCULATION (2011)
Single-dose pharmacokinetics, pharmacodynamics and safety of AZD0837, a novel oral direct thrombin inhibitor, in young healthy male subjects
S. Johansson et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Drug and dietary interactions of warfarin and novel oral anticoagulants: an update
Edith Nutescu et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2011)
Anticoagulant Options - Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran
B. Nhi Beasley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Apixaban in Patients with Atrial Fibrillation
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Dabigatran Etexilate in Clinical Practice: Confronting Challenges to Improve Safety and Effectiveness
Michael P Gulseth et al.
PHARMACOTHERAPY (2011)
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II) A randomised, double-blind, non-inferiority trial
Bengt I. Eriksson et al.
THROMBOSIS AND HAEMOSTASIS (2011)
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial (vol 9, pg 1157, 2010)
H. C. Diener et al.
LANCET NEUROLOGY (2011)
Warfarin Dosing in Patients With Impaired Kidney Function
Nita A. Limdi et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2010)
Extended-Duration Venous Thromboembolism Prophylaxis in Acutely III Medical Patients With Recently Reduced Mobility
Russell D. Hull et al.
ANNALS OF INTERNAL MEDICINE (2010)
National Estimates of Emergency Department Visits for Hemorrhage-Related Adverse Events From Clopidogrel Plus Aspirin and From Warfarin
Nadine Shehab et al.
ARCHIVES OF INTERNAL MEDICINE (2010)
Dabigatran and Warfarin in Vitamin K Antagonist-Naive and -Experienced Cohorts With Atrial Fibrillation
Michael D. Ezekowitz et al.
CIRCULATION (2010)
The importance of appropriate prophylaxis for the prevention of venous thromboembolism in at-risk medical patients
P. Dobesh
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers
Koichiro Ogata et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty
O. E. Dahl et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
New oral antithrombotics: a need for laboratory monitoring. Against
H. Bounameaux et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Direct and indirect costs of management of long-term warfarin therapy in Canada
S. Schulman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial
Lars Wallentin et al.
LANCET (2010)
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
Michael Rud Lassen et al.
LANCET (2010)
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial
Hans Chnstoph Diener et al.
LANCET NEUROLOGY (2010)
Newly Identified Events in the RE-LY Trial
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
Rupert Bauersachs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement.
Michael Rud Lassen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor
Meyer Michel Samama et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
Joanne van Ryn et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Nonadherence in outpatient thromboprophylaxis after major orthopedic surgery: a systematic review
Thomas Wilke et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2010)
American Association of Orthopedic Surgeons and American College of Chest Physicians Guidelines for Venous Thromboembolism Prevention in Hip and Knee Arthroplasty Differ What Are the Implications for Clinicians and Patients?
John W. Eikelboom et al.
CHEST (2009)
Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development
Bengt I. Eriksson et al.
CLINICAL PHARMACOKINETICS (2009)
Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans
Nirmala Raghavan et al.
DRUG METABOLISM AND DISPOSITION (2009)
Kidney Function Influences Warfarin Responsiveness and Hemorrhagic Complications
Nita A. Limdi et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
Alexander G. G. Turpie et al.
LANCET (2009)
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism.
Sam Schulman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement
Michael Rud Lassen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A Cost-Effectiveness Model Comparing Rivaroxaban and Dabigatran Etexilate with Enoxaparin Sodium as Thromboprophylaxis after Total Hip and Total Knee Replacement in the Irish Healthcare Setting
Laura McCullagh et al.
PHARMACOECONOMICS (2009)
Antithrombotic therapy in atrial fibrillation
Daniel E. Singer et al.
CHEST (2008)
Antithrombotic therapy for venous thromboembolic disease
Clive Kearon et al.
CHEST (2008)
Valvular and structural heart disease
Deeb N. Salem et al.
CHEST (2008)
Pharmacology and management of the vitamin K antagonists
Jack Ansell et al.
CHEST (2008)
Prevention of venous thromboembolism
William H. Geerts et al.
CHEST (2008)
Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate
Joachim Stangier
CLINICAL PHARMACOKINETICS (2008)
Apixaban, an oral, direct and highly selective factor Xa inhibitor:: in vitro, antithrombotic and antihemostatic studies
P. C. Wong et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
Ajay K. Kakkar et al.
LANCET (2008)
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
Bengt I. Eriksson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
Michael R. Lassen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement:: the RE-MODEL randomized trial
B. I. Eriksson et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement:: a randomised, double-blind, non-inferiority trial
Bengt I. Eriksson et al.
LANCET (2007)
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Valentin Fuster et al.
CIRCULATION (2006)
The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions
LM DuBuske
DRUG SAFETY (2005)
Functional interaction of intestinal CYP3A4 and P-glycoprotein
KT Kivistö et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2004)
Cytochrome P4502C9 activity in end-stage renal disease
AW Dreisbach et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Validation of clinical classification schemes for predicting stroke - Results from the national registry of Atrial Fibrillation
BF Gage et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Prevalence of diagnosed atrial fibrillation in adults - National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study
AS Go et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Share Paper
